Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- AMERICAN JOURNAL OF KIDNEY DISEASES78(4) · pp.550 · 2021
- 피인용
- Web of Science 33Scopus 41
- FWCI (Scopus)
- 2.25
- JCR IF
- JCR 2020 8.86
- ISSN
- 0272-6386
저자
- 이하린제1저자Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan, South Korea
- Berenger, BrendanUniv Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
- Mehta, Ravindra L.교신저자Univ Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
- Macedo, EtienneUniv Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
초록
Objective: Regional citrate anticoagulation (RCA) is the preferred anticoagulation method for continuous kidney replacement therapy (CKRT) recommended by KDIGO. Limited availability of calcium-free solutions often imposes challenges to the implementation of RCA for CKRT (RCA-CKRT). The principal purpose of this study was to characterize the outcomes of RCA-CKRT using calcium-containing solutions. Study Design: Retrospective cohort study. Setting & Participants: We evaluated the safety and efficacy of RCA-CKRT with calcium-containing dialysate and replacement fluid used for 128 patients. A total of 571 filters and 1,227 days of CKRT were analyzed. Exposures: Liver disease, sepsis in the absence of liver disease, and sepsis with liver disease. Outcomes: Filter life and metabolic complications per 100 CKRT days. Analytical Approach: Linear mixed-effects model and generalized linear mixed-effects models. Results: The majority of patients were male (91; 71.1%), 32 (25%) had liver disease, and 29 (22.7%) had sepsis without liver disease. Median filter life was 50.0 (interquartile range, 22.0-118.0) hours, with a maximum of 322 hours, and was significantly lower (33.5 [interquartile range, 17.5-60.5] h) in patients with liver disease. Calcium-containing replacement solutions were used in 41.6% of all CKRT hours and reduced intravenous calcium requirements by 31.7%. Hypocalcemia (ionized calcium <0.85 mmol/L) and hypercalcemia (total calcium >10.6 mg/dL) were observed in 6.0 and 6.7 per 100 CKRT days, respectively. Citrate accumulation was observed in 13.3% of all patients and was associated with metabolic acidosis in 3.9%, which was not significantly different in patients with liver disease (9.3%; P = 0.2). Limitations: Lack of control groups that used calcium-free dialysate and replacement solutions with RCA-CKRT. Possible overestimation of filter life from incomplete data on cause of filter failure. Conclusions: Our study suggests that RCA-CKRT with calcium-containing solutions is feasible and safe in critically ill patients, including those with sepsis and liver disease.
키워드
CONTINUOUS RENAL REPLACEMENTSYSTEMIC HEPARIN ANTICOAGULATIONCRITICALLY-ILL PATIENTSCARE
식별자
- Scopus EID
- 2-s2.0-85109021999
- WoS UID
- 000702512700014



로그인
연구물 목록으로